BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25376600)

  • 1. Biosimilar insulins: a European perspective.
    DeVries JH; Gough SC; Kiljanski J; Heinemann L
    Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
    Heinemann L; Khatami H; McKinnon R; Home P
    Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar insulins are coming: the top 10 things you should know.
    Blumer I; Edelman S
    Postgrad Med; 2014 May; 126(3):107-10. PubMed ID: 24918796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
    Heinemann L; Davies M; Home P; Forst T; Vilsbøll T; Schnell O
    J Diabetes Sci Technol; 2023 Nov; 17(6):1649-1661. PubMed ID: 35818669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
    Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
    Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological agents and biosimilars: Essential information for the internist.
    Pasina L; Casadei G; Nobili A
    Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2018 Feb; 20(S1):S55-S70. PubMed ID: 29437477
    [No Abstract]   [Full Text] [Related]  

  • 20. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2020 Feb; 22(S1):S32-S46. PubMed ID: 32069160
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.